• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型2-(吲哚-5-基)噻唑衍生物作为黄嘌呤氧化酶抑制剂的设计与合成

Design and synthesis of novel 2-(indol-5-yl)thiazole derivatives as xanthine oxidase inhibitors.

作者信息

Song Jeong Uk, Choi Sung Pil, Kim Tae Hun, Jung Cheol-Kyu, Lee Joo-Youn, Jung Sang-Hun, Kim Geun Tae

机构信息

College of Pharmacy, Chungnam National University, Daejeon 305-764, Republic of Korea; Research & Development, LG Life Sciences Ltd, 188 Munji-ro, Yuseong-gu, Daejeon 305-380, Republic of Korea.

Research & Development, LG Life Sciences Ltd, 188 Munji-ro, Yuseong-gu, Daejeon 305-380, Republic of Korea.

出版信息

Bioorg Med Chem Lett. 2015 Mar 15;25(6):1254-8. doi: 10.1016/j.bmcl.2015.01.055. Epub 2015 Jan 30.

DOI:10.1016/j.bmcl.2015.01.055
PMID:25704891
Abstract

Xanthine oxidase (XO) inhibitors have been widely used for the treatment of gout. Indole rings are frequently used as active scaffold in designing inhibitors for enzymes. Herein, we describe the structure-activity relationship for novel xanthine oxidase inhibitors based on indole scaffold. A series of novel tri-substituted 2-(indol-5-yl)thiazole derivatives were synthesized, and their in vitro inhibitory activities against xanthine oxidase and in vivo efficacy lowering uric acid level in blood were measured. Among them, 2-(3-cyano-2-isopropylindol-5-yl)-4-methylthiazole-5-carboxylic acid exhibits the most potent XO inhibitory activity (IC50 value: 3.5nM) and the excellent plasma uric acid lowering activity. Study of structure activity relationship indicated that hydrophobic moiety (e.g., isopropyl) at 1-position and electron withdrawing group (e.g., CN) at 3-position of indole ring and small hydrophobic group (CH3) at 4-position of the thiazole ring enhanced the XO inhibitory activity. Hydrophobic substitution such as isopropyl at 1-position of the indole moiety without any substitution at 2-position has an essential role for enhancing bioavailability and therefore for high in vivo efficacy.

摘要

黄嘌呤氧化酶(XO)抑制剂已被广泛用于治疗痛风。吲哚环在设计酶抑制剂时经常被用作活性骨架。在此,我们描述了基于吲哚骨架的新型黄嘌呤氧化酶抑制剂的构效关系。合成了一系列新型的三取代2-(吲哚-5-基)噻唑衍生物,并测定了它们对黄嘌呤氧化酶的体外抑制活性以及降低血液中尿酸水平的体内疗效。其中,2-(3-氰基-2-异丙基吲哚-5-基)-4-甲基噻唑-5-羧酸表现出最有效的XO抑制活性(IC50值:3.5 nM)和出色的降低血浆尿酸活性。构效关系研究表明,吲哚环1位的疏水部分(如异丙基)、3位的吸电子基团(如CN)以及噻唑环4位的小疏水基团(CH3)增强了XO抑制活性。吲哚部分1位的疏水取代(如异丙基)且2位无任何取代对于提高生物利用度进而提高体内疗效起着至关重要的作用。

相似文献

1
Design and synthesis of novel 2-(indol-5-yl)thiazole derivatives as xanthine oxidase inhibitors.新型2-(吲哚-5-基)噻唑衍生物作为黄嘌呤氧化酶抑制剂的设计与合成
Bioorg Med Chem Lett. 2015 Mar 15;25(6):1254-8. doi: 10.1016/j.bmcl.2015.01.055. Epub 2015 Jan 30.
2
Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors.新型2-(吲哚-2-基)噻唑衍生物作为黄嘌呤氧化酶抑制剂的基于结构的设计与生物学评价
Bioorg Med Chem Lett. 2016 Feb 1;26(3):950-954. doi: 10.1016/j.bmcl.2015.12.055. Epub 2015 Dec 18.
3
Design, synthesis, and biological evaluation of 5-(1H-indol-5-yl)isoxazole-3-carboxylic acids as novel xanthine oxidase inhibitors.设计、合成及 5-(1H-吲哚-5-基)异恶唑-3-羧酸类化合物作为新型黄嘌呤氧化酶抑制剂的生物评价。
Eur J Med Chem. 2024 May 5;271:116443. doi: 10.1016/j.ejmech.2024.116443. Epub 2024 Apr 26.
4
Design, synthesis, and biological evaluation of N-(3-cyano-1H-indol-5/6-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides and 5-(6-oxo-1,6-dihydropyrimidin-2-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.新型黄嘌呤氧化酶抑制剂 N-(3-氰基-1H-吲哚-5/6-基)-6-氧代-1,6-二氢嘧啶-4-甲酰胺和 5-(6-氧代-1,6-二氢嘧啶-2-基)-1H-吲哚-3-甲腈的设计、合成与生物评价。
Eur J Med Chem. 2022 Jan 5;227:113928. doi: 10.1016/j.ejmech.2021.113928. Epub 2021 Oct 19.
5
Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.设计、合成及生物评价 1-烷基-5/6-(5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)-1H-吲哚-3-甲腈类新型黄嘌呤氧化酶抑制剂。
Eur J Med Chem. 2020 Mar 15;190:112077. doi: 10.1016/j.ejmech.2020.112077. Epub 2020 Jan 21.
6
Amide-based xanthine oxidase inhibitors bearing an N-(1-alkyl-3-cyano-1H-indol-5-yl) moiety: Design, synthesis and structure-activity relationship investigation.含 N-(1-烷基-3-氰基-1H-吲哚-5-基)部分的酰胺基黄嘌呤氧化酶抑制剂的设计、合成及构效关系研究。
Bioorg Chem. 2021 Dec;117:105417. doi: 10.1016/j.bioorg.2021.105417. Epub 2021 Oct 9.
7
2-Benzamido-4-methylthiazole-5-carboxylic Acid Derivatives as Potential Xanthine Oxidase Inhibitors and Free Radical Scavengers.2-苯甲酰胺基-4-甲基噻唑-5-羧酸衍生物作为潜在的黄嘌呤氧化酶抑制剂和自由基清除剂
Arch Pharm (Weinheim). 2017 Feb;350(2). doi: 10.1002/ardp.201600313. Epub 2017 Jan 30.
8
N-(3-cyano-1H-indol-5-yl)isonicotinamide and N-(3-cyano-1H-indol-5-yl)-1H-benzo[d]imidazole-5-carboxamide derivatives: Novel amide-based xanthine oxidase inhibitors.N-(3-氰基-1H-吲哚-5-基)异烟酰胺和 N-(3-氰基-1H-吲哚-5-基)-1H-苯并[d]咪唑-5-甲酰胺衍生物:新型酰胺类黄嘌呤氧化酶抑制剂。
Bioorg Chem. 2021 Oct;115:105181. doi: 10.1016/j.bioorg.2021.105181. Epub 2021 Jul 15.
9
Targeting the subpocket in xanthine oxidase: Design, synthesis, and biological evaluation of 2-[4-alkoxy-3-(1H-tetrazol-1-yl) phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives.靶向黄嘌呤氧化酶的亚口袋:2-[4-烷氧基-3-(1H-四唑-1-基)苯基]-6-氧代-1,6-二氢嘧啶-5-羧酸衍生物的设计、合成与生物评价。
Eur J Med Chem. 2019 Nov 1;181:111559. doi: 10.1016/j.ejmech.2019.07.062. Epub 2019 Jul 24.
10
Design, synthesis and biological evaluation of N-(3-(1H-tetrazol-1-yl)phenyl)isonicotinamide derivatives as novel xanthine oxidase inhibitors.设计、合成及生物评价 N-(3-(1H-四唑-1-基)苯基)异烟酰胺衍生物作为新型黄嘌呤氧化酶抑制剂。
Eur J Med Chem. 2019 Dec 1;183:111717. doi: 10.1016/j.ejmech.2019.111717. Epub 2019 Sep 18.

引用本文的文献

1
Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds.黄嘌呤氧化酶抑制作用的研究进展:潜在生物活性合成化合物综述
Arch Pharm (Weinheim). 2025 Aug;358(8):e70079. doi: 10.1002/ardp.70079.
2
Hyperuricemia in ob/ob mice relates to hepatocellular pyruvate metabolism/ xanthine oxidase axis.ob/ob小鼠的高尿酸血症与肝细胞丙酮酸代谢/黄嘌呤氧化酶轴有关。
PLoS One. 2025 Aug 6;20(8):e0328794. doi: 10.1371/journal.pone.0328794. eCollection 2025.
3
Fangyukangsuan granules ameliorate hyperuricemia and modulate gut microbiota in rats.
复方尿酸康颗粒改善大鼠高尿酸血症及调节肠道菌群。
Front Immunol. 2024 Apr 30;15:1362642. doi: 10.3389/fimmu.2024.1362642. eCollection 2024.
4
Study of the Molecular Architectures of 2-(4-Chlorophenyl)-5-(pyrrolidin-1-yl)-2-1,2,3-triazole-4-carboxylic Acid Using Their Vibrational Spectra, Quantum Chemical Calculations and Molecular Docking with MMP-2 Receptor.利用2-(4-氯苯基)-5-(吡咯烷-1-基)-2H-1,2,3-三唑-4-羧酸的振动光谱、量子化学计算及其与基质金属蛋白酶-2(MMP-2)受体的分子对接研究其分子结构
Pharmaceutics. 2023 Nov 27;15(12):2686. doi: 10.3390/pharmaceutics15122686.
5
Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials.黄嘌呤氧化酶抑制剂的过去、现在与未来:设计策略、结构与药理学见解、专利及临床试验
RSC Med Chem. 2023 Aug 7;14(11):2155-2191. doi: 10.1039/d3md00316g. eCollection 2023 Nov 15.
6
Recent Advances in Xanthine Oxidase Inhibitors.黄嘌呤氧化酶抑制剂的最新进展
Mini Rev Med Chem. 2024;24(12):1177-1186. doi: 10.2174/1389557523666230913091558.
7
A green synthesis and antibacterial activity of ferrocene-based thiazole derivatives in choline chloride/glycerol eutectic solvent.二茂铁基噻唑衍生物在氯化胆碱/甘油低共熔溶剂中的绿色合成及其抗菌活性
RSC Adv. 2022 Aug 9;12(34):22054-22059. doi: 10.1039/d2ra04587g. eCollection 2022 Aug 4.
8
Synthesis and biological evaluation of thiazolidine-2-thione derivatives as novel xanthine oxidase inhibitors.噻唑烷-2-硫酮衍生物的合成及生物评价作为新型黄嘌呤氧化酶抑制剂。
PLoS One. 2022 May 18;17(5):e0268531. doi: 10.1371/journal.pone.0268531. eCollection 2022.
9
From Xanthine Oxidase Inhibition to Hypouricemic Effect: An Integrated Overview of and Studies with Focus on Natural Molecules and Analogues.从黄嘌呤氧化酶抑制到降尿酸作用:聚焦天然分子及其类似物的综合概述与研究
Evid Based Complement Alternat Med. 2020 Feb 25;2020:9531725. doi: 10.1155/2020/9531725. eCollection 2020.
10
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.高尿酸血症相关疾病与黄嘌呤氧化还原酶(XOR)抑制剂:综述
Med Sci Monit. 2016 Jul 17;22:2501-12. doi: 10.12659/msm.899852.